• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Physiologic rationale for calcium antagonist therapy in essential hypertension.

作者信息

Resnick L M

机构信息

Division of Endocrinology/Hypertension, Wayne State University Medical Center, Detroit, Michigan, USA.

出版信息

Ethn Dis. 1998 Winter;8(1):111-9.

PMID:9595255
Abstract

Two basic concepts that are relevant to hypertensive cardiovascular disease are often ignored despite being central to a proper understanding and clinical approach to our patients. First, high blood pressure is an abnormal physical sign; a 'vital' sign, as are temperature, pulse, and respiration. Although people often consider hypertension as a disease, it is itself not a disease, but rather one sign of a disease: a warning manifestation of a disease. Approximately 90% of the time, the underlying cause(s) of this sign are unknown and, thus, the condition itself is named according to its sign, as essential hypertension. Commonly, physicians are told that by eliminating the messenger bearing the bad news--i.e., by merely suppressing the blood pressure, the excess morbidity and mortality associated with the underlying disease process will be reversed. Unfortunately, the cumulative experience of over two decades of world-wide clinical trials indicates that getting rid of only one aspect of hypertensive disease, the elevated blood pressure, gets rid of only part of the excess cardiovascular risk associated with hypertension. By contrast, we now appreciate that what we call hypertension carries with it other peripheral manifestations present in other body systems, such as left ventricular hypertrophy, that may exist prior to and progress independently of the hypertension itself; and insulin resistance, reflecting the same underlying pathophysiology in skeletal muscle, fat, and other tissues. Thus, the disease we call hypertension is not just a 'numbers' game. As such, a reasonable goal not yet attained would be to identify common factors underlying not only the elevations of blood pressure, but the other multisystemic aspects of hypertensive cardiovascular disease as well. Focusing on such underlying factors would allow treatment of the disease process itself, rather than just the level of blood pressure. A second concept, also often overlooked but quite obvious, is the pathophysiologic and clinical heterogeneity of hypertension. People are different. By analogy with an elevated temperature, the same elevation of blood pressure that leads to the diagnosis of 'essential' hypertension may result from many different "primary" causes, which just happen to have hypertension as one shared clinical manifestation. This immediately implies that when we ask, "Is this drug good, or preferred for hypertension?" the answer should be, "It depends." As an obvious example, to be discussed in more detail below, the salt-sensitive hypertensive responds to dietary salt recommendations and to different drug classes differently from an individual who is not salt-sensitive.

摘要

相似文献

1
Physiologic rationale for calcium antagonist therapy in essential hypertension.
Ethn Dis. 1998 Winter;8(1):111-9.
2
Management of vascular risk factors in the hypertensive patient.高血压患者血管危险因素的管理。
J Hum Hypertens. 1990 Oct;4 Suppl 3:10-6.
3
Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.预防和控制高血压的生活方式改变。5. 关于膳食盐的建议。加拿大高血压协会、加拿大高血压预防与控制联盟、加拿大卫生部疾病控制实验室中心、加拿大心脏与中风基金会。
CMAJ. 1999 May 4;160(9 Suppl):S29-34.
4
ESH-ESC guidelines for the management of hypertension.欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)高血压管理指南
Herz. 2006 Jun;31(4):331-8. doi: 10.1007/s00059-006-2829-3.
5
[Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].[心血管疾病中的钙拮抗剂。发病率和死亡率试验的临床证据]
Drugs. 2000;59 Spec No 2:25-37.
6
[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].[慢性肾脏病(CKD)患者的动脉高血压和血脂异常。抗血小板聚集。目标导向治疗]
Nefrologia. 2008;28 Suppl 3:39-48.
7
Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.预防和控制高血压的生活方式改变。1. 方法及加拿大建议概述。加拿大高血压协会、加拿大高血压预防与控制联盟、加拿大卫生部疾病控制实验室中心、加拿大心脏与中风基金会。
CMAJ. 1999 May 4;160(9 Suppl):S1-6.
8
Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).国际硝苯地平控释片研究:高血压治疗目标干预(INSIGHT)中的研究人群与治疗滴定
J Hypertens. 1998 Dec;16(12 Pt 2):2113-6.
9
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.2004年加拿大高血压管理指南:第二部分——治疗
Can J Cardiol. 2004 Jan;20(1):41-54.
10
The 2000 Canadian recommendations for the management of hypertension: Part one--therapy.《2000年加拿大高血压管理指南:第一部分——治疗》
Can J Cardiol. 2001 May;17(5):543-59.